NYSE · CIK 0000946644
AIM AIM ImmunoTech Inc.
Insider trading from SEC Form 4. Last filing 25 d ago. Close $0.18 on Oct 9, 2026, +6% from the 52-week low and -93% from the high.
In brief
AIM ImmunoTech Inc. (AIM) has 55 SEC Form 4 filings on file from 7 insiders, the latest filed on Sep 18, 2026. In the last 90 days insiders made 4 open-market buys worth $13k and 0 open-market sells worth $0, net +$13k.
26 open-market trades have been scored at AIM. The newest: Thomas K Equels (CEO & President) bought $4,992 of stock on Sep 17, 2026, filed Sep 18, 2026, scored 54 (moderate). The largest of the 26 shown: Ted D Kellner (director) bought $50k on Apr 11, 2025, scored 65 (notable). 4 insiders bought within 14 days of each other around Apr 11, 2025.
Last 90 days
Net insider value
+$13k
more bought than sold
Buys
4
$13k by 1 insider
Sells
0
$0 by 0 insiders
Insiders on file
7
with a Form 4 at this company
Price and insider trades, last year
AIMOct 9, 2026 · close 0.18
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at AIM ImmunoTech Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 54Moderate | Thomas K Equels CEO & President buy | $4,992 24,000 shares | +23% | +5% from low-92% from high | |
| 51Moderate | Thomas K Equels CEO & President buy | $2,310 11,000 shares | +12% | 0% from low-92% from high | |
| 54Moderate | Thomas K Equels CEO & President buy | $4,862 22,000 shares | +32% | 0% from low-92% from high | |
| 46Moderate | Thomas K Equels CEO & President buy | $1,292 5,900 shares | +9% | 0% from low-92% from high | |
| 33Weak | Thomas K Equels CEO & President buy | $824 107 shares | +0% | +123% from low-78% from high | |
| 33Weak | Thomas K Equels CEO & President buy | $896 103 shares | +0% | +179% from low-73% from high | |
| 65Notable | Ted D Kellner director buy | $50k 1,968,504 shares | first purchase | 0% from low-90% from high | |
| 80Strong | Thomas K Equels CEO & President buy | $50k 1,968,504 shares | +104% | 0% from low-90% from high | |
| 58Moderate | William M Mitchell director buy | $5,000 196,851 shares | +61% | 0% from low-90% from high | |
| 63Notable | Thomas K Equels CEO & President buy | $2,583 41,000 shares | +2% | 0% from low-71% from high | |
| 48Moderate | Peter W Rodino III COO, Secretary, Gen. Counsel buy | $44 500 shares | +0% | 0% from low-71% from high | |
| 48Moderate | Thomas K Equels CEO & President buy | $6,730 50,000 shares | +3% | +8% from low-58% from high | |
| 48Moderate | Thomas K Equels CEO & President buy | $5,060 44,000 shares | +2% | 0% from low-61% from high | |
| 48Moderate | Thomas K Equels CEO & President buy | $10k 83,334 shares | +5% | 0% from low-61% from high | |
| 46Moderate | Thomas K Equels CEO & President buy | $4,240 20,000 shares | +1% | +17% from low-32% from high | |
| 15Weak | William M Mitchell director sell | $884 4,580 shares | -4% | - | |
| 30Weak | Thomas K Equels CEO & President buy | $4,682 22,727 shares | +1% | - | |
| 32Weak | Stewart Appelrouth director buy | $2,356 11,112 shares | +3% | +22% from low-29% from high | |
| 37Weak | Stewart Appelrouth director buy | $16k 81,953 shares | +34% | +11% from low-35% from high | |
| 44Moderate | Thomas K Equels CEO & President buy | $17k 85,000 shares | +5% | +11% from low-35% from high | |
| 41Moderate | Thomas K Equels CEO & President buy | $11k 60,110 shares | +4% | +11% from low-35% from high | |
| 46Moderate | Nancy Bryan director buy | $15k 38,462 shares | - | +15% from low-46% from high | |
| 63Notable | Stewart Appelrouth director buy | $30k 90,910 shares | +61% | 0% from low-54% from high | |
| 61Notable | Thomas K Equels CEO & President buy | $25k 75,758 shares | +12% | 0% from low-54% from high | |
| 59Moderate | Peter W Rodino III COO, Secretary, Gen. Counsel buy | $13k 37,879 shares | +26% | 0% from low-54% from high | |
| 36Weak | Thomas K Equels CEO & President buy | $15k 33,861 shares | +6% | +39% from low-44% from high |
Transactions
The newest 50 of 59 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 17, 2026 | Thomas K Equels CEO & President | POpen-market purchase Common Stock | +24,000 | $0.21 | $4,992 | 126,822 | 25 d ago |
| Sep 16, 2026 | Thomas K Equels CEO & President | POpen-market purchase Common Stock | +11,000 | $0.21 | $2,310 | 102,822 | 26 d ago |
| Sep 15, 2026 | Thomas K Equels CEO & President | POpen-market purchase Common Stock | +22,000 | $0.22 | $4,862 | 91,822 | 27 d ago |
| Sep 14, 2026 | Thomas K Equels CEO & President | POpen-market purchase Common Stock | +5,900 | $0.22 | $1,292 | 69,822 | 28 d ago |
| Mar 12, 2026 | David I. Chemerow director | CConversion Common Stock | +25,000 | $0.00 | $0 | 28,441 | Mar 16, 2026 |
| Mar 12, 2026 | Thomas K Equels CEO & President | CConversion Common stock | +25,000 | $0.00 | $0 | 63,922 | Mar 16, 2026 |
| Mar 12, 2026 | Thomas K Equels CEO & President | CConversion Series G Convertible Preferred Stockderivative | -25 | $0.00 | $0 | 0 | Mar 16, 2026 |
| Mar 12, 2026 | David I. Chemerow director | CConversion Series G Convertible Prefered Stockderivative | -25 | $0.00 | $0 | 0 | Mar 16, 2026 |
| Mar 6, 2026 | David I. Chemerow director | JOther Series G Convertible Preferred Stockderivative | +25 | $25,000.00 | $625k | 25 | Mar 10, 2026 |
| Mar 6, 2026 | Thomas K Equels CEO & President | JOther Series G Convertible Preferred Stockderivative | +25 | $25,000.00 | $625k | 25 | Mar 10, 2026 |
| Mar 6, 2026 | David I. Chemerow director | JOther Class G Warrantsderivative | +50,000 | $0.00 | $0 | 50,000 | Mar 10, 2026 |
| Mar 6, 2026 | Thomas K Equels CEO & President | JOther Class G Warrantsderivative | +50,000 | $0.00 | $0 | 50,000 | Mar 10, 2026 |
| Feb 5, 2026 | David I. Chemerow director | AGrant or award Common Stockindirect: The David I Chemerow 1992 Trust | +2,800 | $1.23 | $3,444 | 3,441 | Feb 6, 2026 |
| Jun 13, 2025 | Thomas K Equels CEO & President | POpen-market purchase Common Stock | +107 | $7.70 | $824 | 38,885 | Jun 16, 2025 |
| Jun 12, 2025 | Thomas K Equels CEO & President | POpen-market purchase Common Stock | +103 | $8.70 | $896 | 38,675 | Jun 13, 2025 |
| Apr 11, 2025 | Ted D Kellner director | POpen-market purchase Common Stock | +1,968,504 | $0.03 | $50k | 1,969,504 | Apr 23, 2025 |
| Apr 11, 2025 | Thomas K Equels CEO & President | POpen-market purchase Common Stock | +1,968,504 | $0.03 | $50k | 3,867,533 | Apr 23, 2025 |
| Apr 11, 2025 | William M Mitchell director | POpen-market purchase Common Stock | +196,851 | $0.03 | $5,000 | 521,723 | Apr 23, 2025 |
| Apr 4, 2025 | Thomas K Equels CEO & President | POpen-market purchase Common Stock | +41,000 | $0.06 | $2,583 | 1,899,029 | Apr 7, 2025 |
| Apr 4, 2025 | Peter W Rodino III COO, Secretary, Gen. Counsel | POpen-market purchase Common Stock | +500 | $0.09 | $44 | 401,762 | Apr 4, 2025 |
| Mar 14, 2025 | David I. Chemerow director | AGrant or award Common Stock | +44,899 | $0.12 | $5,208 | 64,189 | Mar 18, 2025 |
| Mar 14, 2025 | Nancy Bryan director | AGrant or award Common Stock | +44,899 | $0.12 | $5,208 | 291,882 | Mar 18, 2025 |
| Mar 14, 2025 | William M Mitchell director | AGrant or award Common Stock | +44,899 | $0.12 | $5,208 | 324,872 | Mar 18, 2025 |
| Mar 5, 2025 | Thomas K Equels CEO & President | POpen-market purchase Common Stock | +50,000 | $0.13 | $6,730 | 1,858,029 | Mar 6, 2025 |
| Mar 4, 2025 | Thomas K Equels CEO & President | POpen-market purchase Common Stock | +44,000 | $0.12 | $5,060 | 1,808,029 | Mar 5, 2025 |
| Mar 4, 2025 | Thomas K Equels CEO & President | POpen-market purchase Common Stock | +83,334 | $0.12 | $10k | 1,764,029 | Mar 4, 2025 |
| Feb 28, 2025 | Nancy Bryan director | AGrant or award Common Stock | +38,580 | $0.14 | $5,208 | 246,983 | Mar 4, 2025 |
| Feb 28, 2025 | William M Mitchell director | AGrant or award Common Stock | +38,580 | $0.14 | $5,208 | 279,973 | Mar 4, 2025 |
| Feb 28, 2025 | David I. Chemerow director | AGrant or award Common Stock | +19,290 | $0.14 | $2,604 | 19,290 | Mar 4, 2025 |
| Feb 14, 2025 | Nancy Bryan director | AGrant or award Common Stock | +43,330 | $0.12 | $5,208 | 208,403 | Feb 19, 2025 |
| Feb 14, 2025 | William M Mitchell director | AGrant or award Common Stock | -43,330 | $0.12 | $5,208 | 241,393 | Feb 19, 2025 |
| Jan 31, 2025 | Nancy Bryan director | AGrant or award Common Stock | +25,797 | $0.20 | $5,208 | 165,073 | Feb 3, 2025 |
| Jan 31, 2025 | William M Mitchell director | AGrant or award Common Stock | -25,797 | $0.20 | $5,208 | 198,063 | Feb 3, 2025 |
| Nov 21, 2024 | Thomas K Equels CEO & President | POpen-market purchase Common Stock | +20,000 | $0.21 | $4,240 | 1,657,968 | Jan 21, 2025 |
| Jan 15, 2025 | William M Mitchell director | AGrant or award Common Stock | -27,412 | $0.19 | $5,208 | 172,226 | Jan 17, 2025 |
| Jan 15, 2025 | Nancy Bryan director | AGrant or award Common Stock | +27,412 | $0.19 | $5,208 | 139,276 | Jan 17, 2025 |
| Dec 31, 2024 | William M Mitchell director | AGrant or award Common Stock | +26,305 | $0.20 | $5,208 | 144,854 | Jan 3, 2025 |
| Dec 31, 2024 | Nancy Bryan director | AGrant or award Common Stock | +26,305 | $0.20 | $5,208 | 111,864 | Jan 3, 2025 |
| Dec 31, 2024 | Stewart Appelrouth director | AGrant or award Common Stock | +8,768 | $0.20 | $1,736 | 388,729 | Jan 3, 2025 |
| Dec 19, 2024 | William M Mitchell director | SOpen-market sale Common Stock | -4,580 | $0.19 | $884 | 118,549 | Dec 20, 2024 |
| Dec 18, 2024 | Thomas K Equels CEO & President | POpen-market purchase Common Stock | +22,727 | $0.21 | $4,682 | 1,680,695 | Dec 19, 2024 |
| Dec 13, 2024 | Nancy Bryan director | AGrant or award Common Stock | +24,452 | $0.21 | $5,208 | 85,559 | Dec 17, 2024 |
| Dec 13, 2024 | Stewart Appelrouth director | AGrant or award Common Stock | +24,452 | $0.21 | $5,208 | 379,961 | Dec 17, 2024 |
| Dec 13, 2024 | William M Mitchell director | AGrant or award Common Stock | +24,452 | $0.21 | $5,208 | 123,803 | Dec 17, 2024 |
| Dec 2, 2024 | Stewart Appelrouth director | POpen-market purchase Common Stock | +1 | $0.21 | $0 | 344,398 | Dec 4, 2024 |
| Dec 2, 2024 | Stewart Appelrouth director | POpen-market purchase Common Stock | +11,111 | $0.21 | $2,356 | 355,509 | Dec 4, 2024 |
| Dec 2, 2024 | Nancy Bryan director | AGrant or award Common Stock | +22,645 | $0.23 | $5,208 | 61,107 | Dec 3, 2024 |
| Dec 2, 2024 | Stewart Appelrouth director | AGrant or award Common Stock | +22,645 | $0.23 | $5,208 | 344,397 | Dec 3, 2024 |
| Dec 2, 2024 | William M Mitchell director | AGrant or award Common Stock | +22,645 | $0.23 | $5,208 | 99,351 | Dec 3, 2024 |
| Nov 20, 2024 | Stewart Appelrouth director | POpen-market purchase Common Stock | +81,953 | $0.19 | $16k | 321,752 | Nov 21, 2024 |
50 of 59 rows shown.
Insiders
Everyone who has filed a Form 4 here.
- Stewart Appelrouthdirector
- Nancy Bryandirector
- David I. Chemerowdirector
- Thomas K EquelsCEO & President
- Ted D Kellnerdirector
- William M Mitchelldirector
- Peter W Rodino IIICOO, Secretary, Gen. Counsel
Questions about AIM
Answered from the filings on this page, as of the latest one.
Are insiders buying AIM?
As of Sep 18, 2026, SEC Form 4 filings show 4 open-market buys worth $13k by 1 insider and 0 open-market sells worth $0 by 0 insiders at AIM ImmunoTech Inc. in the last 90 days, net +$13k. Only purchases (code P) and sales (code S) count; grants, option exercises and tax withholding do not.
Who was the last insider to trade AIM on the open market?
Thomas K Equels (CEO & President) bought $4,992 of AIM on Sep 17, 2026 and filed the Form 4 on Sep 18, 2026. InsiderTell scored 54 (moderate).
How many insiders file Form 4 at AIM ImmunoTech Inc.?
7 people have filed a Form 4 at AIM ImmunoTech Inc., among them Stewart Appelrouth (director), Nancy Bryan (director), David I. Chemerow (director). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.